ReviewTherapeutics and clinical risk management2026
Beta-Caryophyllene (BCP) Modulating the Endocannabinoid System and PPARγ to Combat Metabolic Dysregulation: A Narrative Review.
Review in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic diseases are characterized by disruptions in normal metabolic processes and are often caused by genetic, environmental, or lifestyle-related factors. These conditions, including obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, and dyslipidemia, are associated with impaired regulation of glucose and lipid metabolism, chronic inflammation, and insulin resistance. Several studies have also shown that metabolic diseases cause the body to experience a state of dysregulation, characterized by impaired insulin signaling, chronic low-grade inflammation, mitochondrial dysfunction, and abnormal lipid and glucose homeostasis. This review summarizes current research on therapeutic strategies for modulating the molecular pathways involved in metabolic diseases. The primary focus is on the use of beta (β)-caryophyllene (BCP), which has demonstrated therapeutic potential in treatment through various molecular mechanisms involving activation of the endocannabinoid system and PPAR-γ receptors, either directly or indirectly. Crucially, BCP exerts its lipid-lowering and insulin-sensitizing effects by activating the AMPK/SIRT1 signaling pathways and inhibiting HMG-CoA reductase. Evidence from animal studies suggests that BCP reduces oxidative stress and systemic inflammation by lowering the levels of pro-inflammatory cytokines such as TNF-α and IL-6, while improving the expression of adiponectin and leptin. Unlike previous literature that predominantly focuses on isolated cellular pathways, the novelty of this review lies in its comprehensive integration of BCP's pharmacodynamics with its pharmacokinetic (ADME) limitations. By explicitly addressing translational hurdles-such as BCP's extensive first-pass metabolism and the need for advanced self-emulsifying delivery systems (SEDDS)-this work provides a uniquely balanced perspective. A comprehensive synthesis of BCP's molecular mechanisms in metabolic diseases is crucial for exploring its potential as a safer, effective complementary therapy. Given its unique mechanism of action and safety profile, BCP is a promising candidate for further clinical investigation. This review highlights the importance of exploring BCP as a complementary approach for managing metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.